Señales en vivo de PRAX | Maximiza tus Ganancias con Getagraph.com

COMPRAR 112370 min ago

@ $42.09

Emitido: 14 feb 2024 @ 14:09

Retorno: 29.27%

Señal anterior: feb 14 - 10:24

Señal anterior: Vender

Retorno: -4.89 %

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 15:59):

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance...

Stats
Volumen de hoy	155 711
Volumen promedio	209 088
Capitalización de mercado	930.84M
EPS	$0 ( 2024-03-05 )
Próxima fecha de ganancias	( $-2.01 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.91
ATR14	$0.0750 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mastrocola Lauren	Sell	48	Common Stock
2024-02-12	Nemiroff Alex	Sell	51	Common Stock
2024-02-12	Souza Marcio	Sell	271	Common Stock
2024-01-12	Kelly Timothy Edwin	Buy	30 000	Stock Option (Right to Buy)
2024-01-12	Souza Marcio	Buy	100 000	Stock Option (Right to Buy)

INSIDER POWER
98.10
Last 99 transactions
Buy: 3 195 196 \| Sell: 875 304

Volumen Correlación

Largo: -0.18 (neutral)

Corto: -0.13 (neutral)

Signal:(38.464) Neutral

Praxis Precision Correlación

10 Correlaciones Más Positivas
EUSG	0.899
AAWW	0.893
VICR	0.884
CVCY	0.865
CASH	0.861
BPRN	0.859
PXLW	0.848
SMSI	0.842
IMAB	0.839
CIZN	0.837

10 Correlaciones Más Negativas
MOSY	-0.87
APOP	-0.826

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Praxis Precision Correlación - Moneda/Commodity

-0.03
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.21
( neutral )

-0.13
( neutral )

0.37
( neutral )

Praxis Precision Finanzas

Annual	2023
Ingresos:	$2.45M
Beneficio Bruto:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2023
Ingresos:	$2.45M
Beneficio Bruto:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.17M (0.00 %)
EPS:	$-69.33

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.74

Financial Reports:

No articles found.

Praxis Precision

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.